/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

CEL-SCI Corp

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$5.96 -0.14(-14%) CVM at 04 Dec 2025 04:29 PM Biotechnology
Lowest Today 5.67
Highest Today 6.89
Today’s Open 6.89
Prev. Close 6.93
52 Week High 32.70
52 Week Low 1.98
Day’s Range: Low 5.67 High 6.89
52-Week Range: Low 1.98 High 32.70
1 day return -
1 Week return -21.3
1 month return -16.17
3 month return -47.37
6 month return +144.21
1 year return +926.39
3 year return +108.09
5 year return -50.75
10 year return -

Institutional Holdings

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 53.14 M

PB Ratio 7.8853

PE Ratio 0.0

Enterprise Value 63.57 M

Total Assets 26.99 M

Volume 168813

Company Financials

Annual Revenue FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:558664 0.6M

Annual Profit FY24:-3969183 -4.0M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:558664 0.6M

Annual Net worth FY24:-26920465 -26.9M, FY23:-32194303 -32.2M, FY22:-38267691 -38.3M, FY21:-39187563 -39.2M, FY20:-32223336 -32.2M

Quarterly Revenue Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q2/2025:-959009 -1.0M, Q1/2025:-970102 -1.0M, Q4/2024:-991580 -1.0M, Q3/2024:null 0.0M, Q2/2024:-983208 -1.0M

Quarterly Net worth Q2/2025:-5664704 -5.7M, Q1/2025:-6572389 -6.6M, Q4/2024:-7073062 -7.1M, Q3/2024:-6109492 -6.1M, Q2/2024:-6856558 -6.9M

Fund house & investment objective

Company Information CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Organisation Biotechnology

Employees 0

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow